PDF(Pubmed)
Abstract：
UNASSIGNED: Endometriosis presents a significant challenge in gynecological endocrinology, affecting approximately 1 in 10 women of reproductive age. Abdominal wall endometriosis (AWE) and rectosigmoid deep infiltrating endometriosis (DIE) pose unique clinical complexities. High-intensity focused ultrasound (HIFU) has emerged as a novel alternative for treating these conditions, offering a noninvasive option with potential therapeutic benefits.
UNASSIGNED: A systematic review was conducted following PRISMA guidelines to investigate the safety and efficacy of HIFU therapy for AWE and rectosigmoid DIE. The literature search encompassed databases from inception to January 20, 2024. Eligible studies included observational studies, case reports, and clinical trials evaluating HIFU treatment for endometriosis. Data extraction and risk of bias assessment were performed following established protocols.
UNASSIGNED: Fourteen studies were included, comprising 330 patients with AWE and 28 patients with rectosigmoid DIE. HIFU treatment demonstrated significant efficacy, with many patients experiencing complete remission, and clinical effectiveness. Reductions in lesion volume posttreatment were consistent across studies. However, safety concerns were noted, including pain at the treatment site, hematuria, and skin burns. Adverse effects underscored the importance of careful patient selection and monitoring during HIFU therapy.
UNASSIGNED: HIFU therapy shows promise as a noninvasive approach for managing AWE and rectosigmoid DIE. While efficacy outcomes are encouraging, safety considerations warrant attention. Further research, particularly randomized controlled trials with larger sample sizes, is needed to validate findings and optimize treatment protocols.
UNASSIGNED: A systematic review was conducted following PRISMA guidelines to investigate the safety and efficacy of HIFU therapy for AWE and rectosigmoid DIE. The literature search encompassed databases from inception to January 20, 2024. Eligible studies included observational studies, case reports, and clinical trials evaluating HIFU treatment for endometriosis. Data extraction and risk of bias assessment were performed following established protocols.
UNASSIGNED: Fourteen studies were included, comprising 330 patients with AWE and 28 patients with rectosigmoid DIE. HIFU treatment demonstrated significant efficacy, with many patients experiencing complete remission, and clinical effectiveness. Reductions in lesion volume posttreatment were consistent across studies. However, safety concerns were noted, including pain at the treatment site, hematuria, and skin burns. Adverse effects underscored the importance of careful patient selection and monitoring during HIFU therapy.
UNASSIGNED: HIFU therapy shows promise as a noninvasive approach for managing AWE and rectosigmoid DIE. While efficacy outcomes are encouraging, safety considerations warrant attention. Further research, particularly randomized controlled trials with larger sample sizes, is needed to validate findings and optimize treatment protocols.
摘要：
■子宫内膜异位症对妇科内分泌学提出了重大挑战，影响大约十分之一的育龄妇女。腹壁子宫内膜异位症（AWE）和直肠乙状结肠深部浸润型子宫内膜异位症（DIE）构成了独特的临床复杂性。高强度聚焦超声（HIFU）已经成为治疗这些疾病的一种新的替代方法。提供具有潜在治疗益处的非侵入性选择。
■根据PRISMA指南进行系统评价，以研究HIFU治疗AWE和直肠乙状结肠DIE的安全性和有效性。文献检索涵盖从开始到2024年1月20日的数据库。符合条件的研究包括观察性研究，病例报告,和评估HIFU治疗子宫内膜异位症的临床试验。按照既定的方案进行数据提取和偏倚风险评估。
■纳入了14项研究，包括330例AWE患者和28例直肠乙状结肠糖尿病患者。HIFU治疗显示出显着疗效，许多患者经历了完全缓解，和临床有效性。治疗后病变体积的减少在各研究中是一致的。然而,注意到安全问题，包括治疗部位的疼痛，血尿,和皮肤烧伤。不良反应强调了在HIFU治疗期间仔细选择和监测患者的重要性。
■HIFU疗法有望成为治疗AWE和直肠乙状结肠DIE的非侵入性方法。虽然疗效结果令人鼓舞，安全考虑值得关注。进一步研究,特别是样本量较大的随机对照试验，需要验证研究结果并优化治疗方案。
■根据PRISMA指南进行系统评价，以研究HIFU治疗AWE和直肠乙状结肠DIE的安全性和有效性。文献检索涵盖从开始到2024年1月20日的数据库。符合条件的研究包括观察性研究，病例报告,和评估HIFU治疗子宫内膜异位症的临床试验。按照既定的方案进行数据提取和偏倚风险评估。
■纳入了14项研究，包括330例AWE患者和28例直肠乙状结肠糖尿病患者。HIFU治疗显示出显着疗效，许多患者经历了完全缓解，和临床有效性。治疗后病变体积的减少在各研究中是一致的。然而,注意到安全问题，包括治疗部位的疼痛，血尿,和皮肤烧伤。不良反应强调了在HIFU治疗期间仔细选择和监测患者的重要性。
■HIFU疗法有望成为治疗AWE和直肠乙状结肠DIE的非侵入性方法。虽然疗效结果令人鼓舞，安全考虑值得关注。进一步研究,特别是样本量较大的随机对照试验，需要验证研究结果并优化治疗方案。
